Enarodustat
Phase 3Small molecule
Enarodustat is one of 91 small molecule programs targeting Anemia. It is currently in Phase 3.
2
Indications
3
Total Trials
3
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
169 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Enarodustat
SShenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 3
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
PROCRIT
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enarodustat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details